Shelley Starck Email & Phone Number

Alameda, California, Us

I led an initiative to identify a differentiated therapeutic strategy to reverse myeloid checkpoint activity and augment anti-tumor immunity.• Research Director for all internal discovery and preclinical program activities• Technical Director for therapeutic antibody and protein target design, engineering, and production to achieve ideal antibody pharmacology• Immuno-oncology target identification to guide program POC and MOA activities/timelines

South San Francisco, Ca, Us

I conceived and led early discovery biologics-based research programs in oncology and ophthalmology.• Emerging technology group leader for cross-functional biology and biologics activities• New antibody modality design for new targets and indications with provisional patent authorship• Protein science group leader for immuno-oncology antibody targets from discovery to IND-enabling activities• Transgene engineering to achieve ideal pharmacology, optimize antibody specificity, and guide POC and MOA activities

San Francisco, California, Us

• I invented and developed a novel technique to explore the translational ‘hot-spots’ of cellular mRNAs, including the noncoding regions of the genome (e.g., 5’ UTR); see Starck, S.R. et al. Science 2016• This concept has been applied in the commercial space for cancer vaccines, cell therapy, and protein-based modalities for solid tumor-targeting(Starck et al., Science 29 Jan 2016: Vol. 351, Issue 6272, aad3867; DOI: 10.1126/science.aad3867)

Berkeley, Ca, Us

• I created and implemented a variety of biochemical, cell-based, and mouse immunization models to show for the first time that ribosomes use a distinct translation initiation pathway to select non-AUG start codons, such as CUG, to initiate protein synthesis for presentation of MHC-I peptides; see Starck S.R. et al. Science, 2012 (Starck et al., Science 29 Jun 2012: Vol. 336, Issue 6089, pp. 1719-1723)

Berkeley, Ca, Us

I developed a cell-based approach to decipher the molecular mechanism of microRNA (miRNA)-mediated translation repression in mammalian cells.

Pasadena, Ca, Us

I developed a variety of chemical, biochemical, and cell-based approaches to study and monitor the peptidyl transferase reaction in the ribosome and visualize global protein synthesis in living cells and tissues.

Ph.D., Chemistry; Biochemistry Specialization

B.S., Chemistry; Biochemistry Specialization

Postdoctoral Training, Molecular Immunology